著者

中川 祐紀子 鈴木 拓也 志村 裕介 菅 幸生 嶋田 努 崔 吉道

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.43, no.1, pp.26-33, 2017-01-10 (Released:2018-01-10)

参考文献数

10

被引用文献数

2 3

---

The ward pharmacist received a report from ward nursing staff that an aggregation formed when lansoprazole OD tablets and ground levofloxacin tablets were suspended simultaneously in water. In this study, we elucidated the factors of aggregation focusing on additives, the main drug, and pH in suspension, and also considered ways of preventing the aggregation. To elucidate the contribution of additives in levofloxacin tablets, drugs containing similar additives to those of levofloxacin tablets were suspended with lansoprazole OD tablets in water, but no aggregation was observed. Levofloxacin hydrate intravenous drip infusion (pH 4.8) did not form an aggregation with lansoprazole OD tablets, meanwhile levofloxacin hydrate intravenous drip infusion adjusted to pH 7.3 and levofloxacin hydrate solution adjusted to pH 7.3 formed an aggregation with lansoprazole OD tablets. When lansoprazole OD tablets and ground levofloxacin tablets were suspended in a buffer solution of pH 5.0, pH 6.0, and pH 7.0, no aggregation was observed in a buffer solution of pH 5.0. When generic lansoprazole OD tablets and generic lansoprazole capsules were suspended with levofloxacin tablets in water, aggregation was also observed. On the other hand, the aggregation of lansoprazole OD tablets was not observed when lansoprazole OD tablets and levofloxacin tablets were suspended in apple juice. According to the above results, factors related to the formation of the aggregation were involved in the preparation of lansoprazole, levofloxacin hydrate, and around pH 6.0, and the suspending of lansoprazole OD tablets and levofloxacin tablets simultaneously in acidic drinks such as apple juice is means of avoiding the aggregation.

著者

山本 奈歩 堀 祐貴 髙廣 理佳子 菅 幸生 嶋田 努 崔 吉道

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.45, no.3, pp.127-134, 2019-03-10 (Released:2020-03-11)

参考文献数

19

被引用文献数

2

---

Albumin-bound paclitaxel (nab-PTX) plus gemcitabine (GEM) therapy (GnP) is often administered to patients with unresectable metastatic pancreatic cancer. However, chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect. In this study, we investigated the risk factors for CIPN in patients who were receiving GnP therapy for pancreatic cancer at our hospital and had a history of prior chemotherapy. The patientsʼ background, laboratory data, previous treatment history, concomitant medication, dose and number of medicines, and occurrence status of side effects were examined. The frequency of CIPN in patients receiving GnP therapy at our hospital was 72%. Multiple logistic regression analysis revealed that a history of FOLFIRINOX therapy (FFX), including oxaliplatin (L-OHP) administration, (odds rate: 3.864, 95% CI: 1.160-12.868) and female sex (odds rate: 3.673, 95% CI: 1.102-12.242) were risk factors for CIPN. In addition, the severity of CIPN was significantly higher in patients with a history of FFX administration (P = 0.011). Further, the cumulative dose and the administration period of nab-PTX until the onset of CIPN were significantly lower in patients with a history of FFX administration (P = 0.016, P = 0.004, respectively). We suggest that special care in monitoring GnP therapy is necessary in female patients with a history of FFX administration.

著者

伊藤 智代 中出 順也 嶋田 努 崔 吉道

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.44, no.8, pp.403-409, 2018-08-10 (Released:2019-08-14)

参考文献数

12

---

FOLFIRINOX is a novel chemotherapy that has been approved for the treatment of advanced pancreatic adenocarcinoma. In comparison with the conventional gemcitabine single agent therapy, FOLFIRINOX is advanced for objective responses, progression-free survival, and median overall survival. Cholinergic syndromes are frequently observed in patients receiving FOLFIRINOX and have been suggested to occur due to the inhibition of acetylcholinesterase by irinotecan (CPT-11). However, no research has been performed on the incidence and risk factors of cholinergic syndromes under FOLFIRINOX. This study aimed to evaluate the incidence and risk factors of cholinergic syndromes induced by FOLFIRINOX in retrospective investigation. Forty-eight patients who were treated with the first cycle of FOLFIRINOX were analyzed and 33 (68.8%) of those experienced cholinergic syndromes including diaphoresis (50.0%), acute diarrhea (33.3%), abdominal pain (29.2%), dysarthria (8.3%), and one for each case of bradycardia, nasal flow, miosis and numbness in the hands. Diaphoresis was experienced more frequently in younger patients (P = 0.029). Other characteristics of patients had no significant relationship with the induction of cholinergic syndrome; sex, stage of cancer, performance status, prior chemotherapy, dose of CPT-11, use of opioid, use of NSAIDs and/or acetaminophen and UGT1A1 genotype. This study indicated for the first time that cholinergic syndromes are observed in almost 70% of patients treated with FOLFIRINOX, and it might be due to the combination of CPT-11 and oxaliplatin. Since cholinergic syndromes can deteriorate the quality of life, patients should be monitored carefully regardless of their characteristics under FOLFIRINOX.

著者

赤瀬 智子 嶋田 努 原沢 友紀子 赤瀬 朋秀 池谷 幸信 田代 眞一 油田 正樹

出版者

ライフサイエンス出版

雑誌

薬理と治療 = Basic pharmacology and therapeutics (ISSN:03863603)

巻号頁・発行日

vol.36, no.1, pp.39-48, 2008-01-01

---

「はじめに」近年先進国において増加しているMetS(内臓脂肪症候群)は動脈硬化性疾患(心筋梗塞や脳梗塞など)の危険性を高めるマルチプルリスクファクター症候群のことである. 動脈硬化性疾患は肥満症, 高血圧症, 高脂血症, 耐糖能異常, 高インスリン血症などの代謝性疾患が重なることによって発症頻度が増加するといわれている1). 日本では, MetSが強く疑われる者と予備群と考えられる者をあわせた割合は男女とも40歳以上でとくに多く, 40~74歳の男性2人に1人, 女性では5人に1人, 約1900万人がMetSおよびその予備軍であると推定され, 深刻な社会問題となっている2). 2005年4月に日本肥満学会, 日本動脈硬化学会, 日本糖尿病学会など8学会により, 日本におけるMetsの診断基準が定義された3). MetSの背景には, 食生活の欧米化により増加した肥満の存在がある. 肥満による内臓脂肪の増加がこの疾患に深く関与していることが明らかになっている4). In recent years the number of patients with metabolic syndrome (MetS) has been increasing in advanced countries, and the condition is now becoming a serious problem in Japan. In Sri Lanka, a perennial liana, Salacia reticulata (Kotala himbutu), has traditionally been used in Ayurveda (Ayurvedic medical care) for the treatment of diabetes (mellitus) and skin diseases. Some reports have recently shown that components of the plant's extracts have an inhibitory action against elevation of blood sugar, antiobesity actions, protective action on the liver, antioxidant actions, etc. In the present study, the effects of a mixture of Kotala himbutu aqueous extract and cyclodextrin (KH) were investigated on the various morbidities of MetS in animal models of MetS, TSOD mice. The animals were given, normal feed (MF) containing the powder of KH at concentrations 1% or 3%, for 8 weeks. Then, the body weight, amount of food intake and the serum insulin levels in the animals were measured. Determination of the serum biochemistry, X-ray computed tomography (CT) to determine the visceral and subcutaneous fat areas, measurement of blood pressure, the pain test and glucose tolerance test were also conducted. Significant inhibitions of weight gain and of visceral and subcutaneous fat accumulation were noted from the early stage of administration of KH. Serum biochemical examination revealed decreases in the blood sugar, T-Cho, LDL-Cho and HDL-Cho levels. The findings confirmed a significant beneficial effect of KH on impaired glucose tolerance, hypertension and peripheral neuropathy.